Introduction
The Antihypertensive and Lipid-Lowering to Prevent Heart Attack Trial (ALLHAT) -a major randomized active-controlled (comparative effectiveness) trialpublished its main findings in December 2002 and September 2003 [1] [2] [3] . The largest hypertension clinical trial ever conducted, it enrolled 42 418 demographically and clinically diverse high-risk patients with hypertension. The results of the trial influenced clinical practice [4, 5, 6 -9 ] and generated considerable discussion, as some of the results seemed unexpected [10] [11] [12] [13] [14] . Since the initial publications, new clinical trials and metaanalyses have been reported, and ALLHAT data have continued to be analyzed [15-17,18 ,19 ,20-32,33 ,34, 35 ,36 ,37] . In May 2009, the ALLHAT Steering Committee published a review manuscript to reassess the trial's conclusions in light of up-to-date information [38 ] . Here, we summarize and update this review with special emphasis on heart failure findings, results in Black participants, selection and doses of thiazide and similar diuretics (simply termed thiazides), patients with chronic kidney disease (CKD), and the association of antihypertensive drug use with new-onset diabetes and its cardiovascular consequences.
ALLHAT: background and objectives
When the ALLHAT trial was funded in 1993, it was well established that treatment of hypertension with thiazides compared with placebo or usual care reduces mortality by up to 20% and prevents stroke, heart failure, and myocardial infarction (MI) by about 40, 50 , and 20%, respectively [39] [40] [41] [42] . New drugs developed in the late 70s and in the 80s -calcium antagonists (CCBs), angiotensinconverting enzyme inhibitors (ACEIs), and a-receptor blockers -were shown to have more favorable metabolic profiles in short-term studies than the well established a thiazides. Therefore, a logical expectation was that these newer agents would have better long-term cardiovascular outcomes, especially for coronary heart disease (CHD). (12. 5-25 mg/day)], in the strongest possible design -a randomized, double-blind trial [43] . Each drug was used as first-step treatment with other drugs added to achieve a blood pressure (BP) goal of less than 140/90 mmHg. A composite of CHD death and nonfatal MI was designated as the primary endpoint. Prespecified secondary endpoints included combined cardiovascular disease and its components (the primary endpoint, heart failure, stroke, coronary revascularization, angina, and peripheral vascular disease) as well as end-stage renal disease (ESRD). To optimize statistical power for multiple comparisons, the randomization ratio was 1.7 : 1 for the thiazide versus each of the comparator drugs. As noted by Neaton and Kuller [44] , ALLHAT was the only hypertension trial with adequate power to detect moderate (i.e. 16% relative difference in CHD) but important differences in several major clinical outcomes.
ALLHAT: principal findings
After up to 8 years of follow-up (average 4.9 years in the CCB or ACEI versus thiazide comparison and 3.2 years in the a-blocker versus thiazide comparison, which was terminated early), we concluded that the thiazide-based treatment was superior to each of the three comparator drugs in significantly preventing one or more major forms of cardiovascular disease (CVD) and unsurpassed in preventing any outcome. Specifically (Fig. 1 . Except for race (see below), results in prespecified subgroups (age, sex, and diabetes) were remarkably consistent (Fig. 2) [1, 3, 27] . Post-hoc subgroup analyses by metabolic syndrome at baseline, with and without diabetes [25, 26] , were consistent with the overall results and with the results in those with diabetes at baseline [1, 27] . Similarly, outcomes stratified by eGFR at baseline were consistent with the overall results [24] . These subgroup results provide further support for the ALLHAT and the Seventh Report of Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7) recommendation that thiazides should be preferred for first-step antihypertensive treatment in most patients, including those with diabetes, metabolic syndrome and renal impairment.
Black patients with hypertension
Black individuals have been long recognized to have the highest prevalence and earliest onset of hypertension. Hypertension is also a major contributor to the racial gap in cardiovascular mortality between Whites and Blacks in the US. Notably, in Black individuals aged 40 and over, awareness of hypertension is high (71-83% across sex/age groups) and a large majority of those aware of their hypertension report being treated (83-97% across sex/ age groups). However, the proportion of treated Black patients with BP controlled to below 140/90 mmHg remains low [45 ,46] . With 15 094 Black participants, ALLHAT is the only randomized clinical trial to provide long-term BP control and major cardiovascular outcomes data on treatment of hypertension with drugs other than thiazides in this subgroup.
The results are very clear: the use of thiazides as initial treatment of hypertension is even more compelling for Blacks because of the 40% increased risk of stroke (P < 0.001) and 19% increased risk of CCVD (P < 0.001) with ACEI versus thiazide. For both Blacks and non-Blacks, there was a lower risk of heart failure for chlorthalidone versus all three comparator drugs and of CCVD and stroke versus a-blocker. Notably, the newer drugs were not significantly superior to chlorthalidone for any of the major clinical outcomes (Figs 2 and 3) [30] . We have also shown that these findings extend to individuals with metabolic syndrome, both Black and nonBlack (Table 1) [25, 26] .
Unlike the other two classes, there was little difference [less than 1 mmHg at 4 years (P < 0.05)] in BP lowering between the thiazide and the CCB and the only difference in outcomes was a significantly higher rate of heart failure. However, compared with the thiazide, the ACEI was less effective in lowering BP, primarily in Black participants, and associated with significantly higher risks of stroke, heart failure, and overall CVD. At 4 years, SBP/ DBP was 3.5/1.0 mmHg higher in Black participants versus SBP 0.6 mmHg higher and DBP 0.2 mmHg lower in non-Blacks. Overall, SBP/DBP was 1.6/0.1 higher in the ACEI compared with the thiazide. Similarly, the a-blocker was less effective than the thiazide in lowering BP (þ2.1/þ0.1 mmHg at 4 years) and associated with significantly higher risks of HF, stroke and CCVD, as well as cardiovascular and stroke mortality (Figs 2 and 3) [30, 38 ].
Prevention of heart failure
The prevention of heart failure is an important goal of antihypertensive management in clinical practice. Newonset heart failure is a common complication of hypertension, the most common diagnosis-related group (DRG) for hospitalized Medicare beneficiaries [47] , and is associated with very high subsequent mortality. In ALLHAT, 6-year incidence rates of centrally adjudicated hospitalized heart failure were comparable in magnitude to those of stroke (5.6%) and to about half those of CHD (11.4%). The magnitude of the mortality rates subsequent to hospitalized heart failure (more than 50% at 5 years) further underscores the importance of prevention [32, [48] [49] [50] .
Heart failure validation study
In the main results manuscripts, we reported that the risk of developing new-onset heart failure was higher for each of the comparator drugs than for the thiazide by 38 (P < 0.01), 20 (P < 0.001), and 80% (P < 0.001) for the CCB, ACEI, and a-blocker, respectively ( Fig. 1 ) [1, 3] . Some found these results unexpected, especially with respect to the ACEI, and raised questions about validity of the results [10, 11, 51, 52 ]. An extensive validation study, which centrally adjudicated all hospitalized heart failure events, confirmed the initial results [32] . Importantly, reporting bias was not an issue because ALLHAT was double-blinded and procedures were in place to prevent under-reporting of events [32] .
Heart failure with preserved versus reduced ejection fraction
Among source documentation, the ALLHAT Heart Failure Validation Study collected information on LVEF during heart failure hospitalizations [32] . These data provided further information on prevention of new-onset heart failure in high-risk hypertensive patients [34] . We reported that the thiazide significantly reduced the risk of heart failure with preserved LVEF (!50%) compared with the CCB, ACEI, or a-blocker; the hazard ratios were 0.69 (P ¼ 0.009), 0.74 (P ¼ 0.032), and 0.53 (P < 0.001), respectively. The risk of heart failure with reduced LVEF was also decreased by the thiazide compared with ALLHAT: still providing correct answers Einhorn et al. 359
Figure 3 Kaplan-Meier plots for outcomes by treatment group by race (solid line, chlorthalidone; dotted line, amlodipine besylate; dashed line, lisinopril; dot-dash line, doxazosin mesylate)
the CCB or a-blocker (hazard ratios 0.74; P ¼ 0.013 and 0.61; P < 0.001, respectively), and similar to the ACEI (hazard ratio 1.07; P ¼ 0.596). These results are remarkably consistent with placebo-controlled trials: for the thiazide, 49% decreased risk (P < 0.001) -based on SHEP (chlorthalidone AE atenolol) and 64% -based on HYVET (P < 0.001, sustained release indapamide AE perindopril, participants aged !80 years); for ACEI, 20% (P < 0.001) risk reduction in SOLVD Prevention (captopril, participants with reduced LVEF), 23% (P < 0.001) in HOPE (ramipril), and 25% (P ¼ 0.02) in PEACE (trandolapril, participants with preserved LVEF) [19 ,42,53-56] .
Early benefit of chlorthalidone for preventing new-onset heart failure
The greatest benefit of the thiazide for hospitalized or fatal heart failure prevention occurred during year 1. The relative risk of developing heart failure in those assigned the CCB, ACEI, or a-blocker was substantially greater than in those on the thiazide. After year 1, there was no further increase in relative risk in the ACEI versus thiazide arm [31] . In the CCB and a-blocker arms, the risk of developing new-onset heart failure versus thiazide continued to increase beyond year 1, though at slower rates (RR 1.22; 95% CI 1.08-1.38 and 1.28; 95% CI 1.10-1.49, respectively) [31,38 ,57] .
In seeking explanations for the early benefit of the thiazide, we also explored an issue of whether discontinuation of medications at study entry could contribute to the excess new-onset heart failure in the other drugs compared with the thiazide. Whereas information about prior medications was not collected at ALLHAT baseline, using infrastructure provided by the ALLHAT Heart Failure Validation Study [32] , we obtained pretrial medication history from the clinics to conduct a case-only analysis within those who developed new-onset heart failure. We found that pre-entry drug type did not explain the observed excess of new-onset heart failure in the ACEI, CCB, or a-blocker-based treatments compared with the thiazide-based therapy [33 ,58,59] .
Atrial fibrillation
Atrial fibrillation, the most common clinically significant cardiac arrhythmia, is associated with markedly increased risks of stroke, heart failure and death. Hypertension is an important risk factor for atrial fibrillation. We have just published the results of an ALLHAT ancillary study of atrial fibrillation at baseline and during follow-up [36 ] . There were two important findings in this report. First, the report confirmed both the lesser prevalence and lower new-onset incidence of atrial fibrillation in Black versus non-Black individuals. The odds of having atrial fibrillation on baseline ECGs were two-fold higher for non-Black versus Black participants, even after adjustment for relevant demographic and clinical characteristics. (Of note, ALLHAT recruitment criteria excluded those with symptomatic heart failure or LVEF <35%.) Also, the odds of developing new-onset atrial fibrillation during follow-up in Black individuals were about 60% compared with non-Black individuals.
Second, except for the a-blocker versus thiazide comparison, the ECG-based incidence of atrial fibrillation did not differ by antihypertensive treatment group. In those randomized to the a-blocker-based treatment, the risk of developing atrial fibrillation was 35% higher compared with those assigned to the thiazide-based regimen (P ¼ 0.02).
Patients with chronic kidney disease
Among antihypertensive treatment trials, ALLHAT had one of the largest cohorts of patients with at least stage 2 CKD. Though known serum creatinine above 2 mg/dl was an exclusion criterion, approximately 17% of participants (N ¼ 7175) had an entry eGFR below 60 ml/min/ 1.73 m 2 , consistent with CKD [22] . ALLHAT has provided important information in this area: participants with CKD are much more likely to have prevalent CVD [22] and also to develop CVD over time compared with participants without CKD [24] . In fact, older patients with CKD are much more likely to develop or die of CVD than to progress to ESRD requiring dialysis.
Neither the CCB nor the ACEI was superior to the thiazide in preventing significant declines in GFR or progression to ESRD [23] . While these results may seem inconsistent with previous studies showing beneficial effects of the renin-angiotensin axis inhibitors (RAS inhibitors) [60] [61] [62] , there are important differences between ALLHAT and traditional renal studies. Most ACEI/ARB studies used thiazides as second-line agents or in combination rather than in direct comparison with RAS inhibitors. In addition, the renal studies often had patients with more advanced CKD and proteinuria.
ALLHAT provides the most robust cardiovascular outcome data in CKD currently available in the literature. Most previous studies were either underpowered or did not adequately ascertain cardiovascular outcomes. In ALLHAT, neither the CCB nor the ACEI-based therapy was superior to the thiazide-based therapy in preventing cardiovascular outcomes in the CKD subgroup [24] .
Most CKD patients require multiple drug therapy to achieve BP goals. The National Kidney Foundation guidelines on hypertension management in CKD recommend that 'Most patients with CKD should be treated with a diuretic'; thiazide diuretics are recommended in patients with GFR at least 30 ml/min/1.73 m 2 , and loop diuretics in those with more advanced CKD [63] .
Glucose metabolism and incident diabetes
An important ALLHAT rationale was to determine whether newer drugs with more favorable effects on glucose and other metabolic parameters would result in a lower incidence of major clinical outcomes, especially coronary events. As described above, they did not. We explored this issue in detail in a separate manuscript and in the recent review. The evidence was consistent in showing no increase in CVD outcomes associated with diuretic-induced new-onset diabetes [29, 38 ]. Although counterintuitive, it is important to recognize that the increase in glucose levels with the use of thiazides and contributing to incident diabetes is relatively small (4-6 mg/dl). Though some have suggested that the follow-up may have been of inadequate duration [64] , neither in ALLHAT nor in meta-analyses of thiazide cardiovascular outcome trials has a signal for adverse effect of these agents on CVD been appreciated [38 ] . In ALLHAT, overall new-onset diabetes was associated with a 64% increase in CHD (CI 1.15-2.32) compared with nondiabetics, and the hazard ratio was 2.23 (1.07-4.62) in those randomized to the ACEI [29] . Notably, the majority of new-onset type II diabetes occurring with the use of thiazides, as with other antihypertensives, may be due to factors such as aging and weight gain with little additional drug-specific (drug-induced) effect. In ALLHAT at 2 years of follow-up, 9.3% of participants had developed new-onset diabetes mellitus in the chlorthalidone groups versus 7.2% in the amlodipine group, suggesting that, among participants on chlorthalidone, about 80% of incident diabetes at 2 years was not due to chlorthalidone [29] .
The issue is difficult to study because it is not possible to randomize participants to develop or not develop diabetes. ALLHAT findings based on postrandomization stratification by incident diabetes suggest that incident diabetes occurring in the thiazide arm may be heterogeneous, with the thiazide-induced cases having less adverse outcomes. It is also possible that drug combinations that would prevent thiazide-induced diabetes, including potassium supplementation, may result in even better long-term clinical outcomes. Mechanistic studies in the context of properly designed clinical trials are needed to address this important clinical issue [65] . It is also important to recognize that no evidence exists to support better clinical outcomes in relationship to prevention of diabetes with ACEIs or, as noted by Mendoza and Stevermer [66] , lisinopril (in ALLHAT) reduced the onset of diabetes over 5 years at the cost of increase in HF and CCVD.
On the basis of results of recently reported comparative trials, prominent hypertension researchers raised questions about a fixed relationship between BP lowering and outcome benefit at least at all BP ranges, at all levels of cardiovascular risk and with all drug combinations [67] . ALLHAT results also raised this issue, and so did other trials reported shortly afterwards [16, 17] . We have addressed this topic in the Wright et al. [38 ] review and concluded that small BP differences seen in ALLHAT may account for some, but not all, of the advantages seen with the thiazide.
Other trials
Two more recent trials deserve special mention. Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) was the first double-blind randomized trial designed to compare two fixed-dose double-drug combinations. In one arm, benazepril was combined with amlodipine besylate (5-10 mg), in the other with hydrochlorothiazide (12.5-25 mg) [18 ] . The dose of amlodipine besylate was the same as in ALLHAT; the dose of the thiazide was roughly equivalent to half of the 12.5-25 mg of chlorthalidone used in ALLHAT. The trial was stopped early by its data and safety monitoring board for marked benefit in the ACEI/CCB arm of the trial on CVD outcomes. It highlighted the need for the treatment recommendations to include evidence-based dosing and revived decades-old discussion about the type and the dose of diuretics [68 ] . For the purpose of this review, it is important to note that trials in which hydrochlorthiazide was associated with favorable reductions in cardiovascular events used higher doses (25-50 mg/day) than currently advocated and used in fixed-dose drug combinations [38 ,68 ] .
The Hypertension in the Very Elderly Trial (HYVET) addressed a very important clinical question of whether antihypertensive treatment of individuals aged 80 and over is beneficial [19 ] . There was a concern that antihypertensive therapy in the very elderly may reduce the risk of stroke but increase the risk of death from other causes. A double-blinded, randomized, placebocontrolled trial, HYVET enrolled 3845 patients who were 80 years of age or older and had sustained SBP between 160 and 199 mmHg. Patients were randomized to receive a thiazide (sustained release indapamide 1.5 mg) or a matching placebo. The ACEI (perindopril 2 or 4 mg), or matching placebo, was added if necessary to achieve the target BP of 150/80 mmHg or less. (The use of additional antihypertensive agents for more than 3 months resulted in withdrawal of patients from double-blinded follow-up.)
After an average follow-up of 2.1 years, the investigators reported a 21% statistically significant reduction in total mortality (P ¼ 0.02). There was also a 64%, highly significant (P < 0.001), reduction in fatal and nonfatal heart failure and a 34% reduction (P < 0.001) in combined major CVD events. The primary endpoint, fatal or nonfatal stroke, was reduced by 30%, but failed to reach a nominal statistical significance of less than 0.05. (Stroke mortality was reduced by 39%; P ¼ 0.046.) Fewer adverse events were reported in the active-treatment versus placebo group. Thus, HYVET demonstrated that antihypertensive treatment with a thiazide, with or without ACEI, in persons 80 years or older is beneficial.
ALLHAT enrolled 14 890 participants aged 70 and above (2765 aged 80 and above). Although more detailed presentation of ALLHAT data in older hypertensive individuals is forthcoming, we have already reported similarity of treatment effects in the prespecified subgroups of above and below age 65 ( Fig. 2) [1].
Conclusion
In summary, the up-to-date evidence remains consistent in confirming the initial ALLHAT findings that neither a-blockers nor ACEIs or CCBs surpass thiazides (at appropriate dosage) as initial antihypertensive therapy for the reduction of cardiovascular or renal risk. Thiazides are superior in preventing one or more major forms of CVD, including heart failure, versus all three comparator drugs, and stroke and combined cardiovascular outcome versus ACEIs and a-blockers. The recommended dose of the thiazide is an equivalent of 12.5-25 mg of chlorthalidone (roughly 25-50 mg of hydrochlorothiazide). The dose may be especially important for stroke prevention. Longer-acting thiazides may have added outcome benefits, but even without that evidence they are more forgiving of missed doses. We also hypothesized -based on many clinical trials -that adding an ACEI to a thiazide may optimize heart failure prevention [34] .
Recommendation
Given the totality of evidence, we re-affirm the initial ALLHAT conclusion that thiazide and similar diuretics (at evidence-based doses) are the preferred first-step therapy in most patients with hypertension. Future analyses of biomarkers and genes in the ALLHAT population may set the stage for development of more personalized treatment recommendations. This study evaluates the impact of the ALLHAT/JNC-7 Dissemination Project's academic detailing component on thiazide and similar diuretics prescribing using two complementary national databases available from IMS Health (Plymouth Meeting, PA). The outcomes were analyzed at a county level by intensity (dose) of intervention. The results showed that the program was associated with a small increase in diuretic prescribing, which was consistent with the small dose of intervention (1698 presentations by 147 investigator-educators reached 18 524 physicians), and thus demonstrated that academic detailing has the potential to increase physicians' implementation of clinical trial results, thereby making prescribing more consistent with evidence.
